Case Report of a Patient Undergoing Peritoneal Dialysis with Encapsulating Peritoneal Sclerosis Superimposed With Calciphylaxis.

Introduction: Encapsulating peritoneal sclerosis (EPS) is a rare but devastating complication of peritoneal dialysis (PD). Tamoxifen has been generally well-tolerated, even without randomized controlled trials.
Case Presentation: Herein, we report a case of a patient undergoing 12 years of PD who developed EPS and calciphylaxis simultaneously. We also provide a comprehensive discussion about the association between EPS and calciphylaxis. Moreover, although tamoxifen is used in EPS due to its inhibition of fibroblast-transforming growth factor beta (TGFβ) production, it may worsen the calciphylaxis due to a hypercoagulable state.
Conclusions: We suggest avoiding the use of tamoxifen for EPS in patients with superimposed calciphylaxis.
Competing Interests: Conflict of Interest:We do not have any relationships with pharmaceutical companies or other entities, such as employment contracts, consultancy, advisory boards, speaker bureaus, membership on boards of directors, or stock ownership that could be perceived to represent a financial conflict of interest.